Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (221-230 of 379) with videos related to

Pageof 38
Sort By:
Immunotherapy|March 31, 2017
Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doorsChristian Baues, Maike Trommer-Nestler, Karolina Jablonska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin LymphomaBastian von Tresckow, Franck Morschhauser, Vincent Ribrag, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Plos One|October 15, 2008
Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer functionVenkateswara Rao Simhadri, Katrin S Reiners, Hinrich P Hansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 TrialsStephanie Sasse, Paul J Bröckelmann, Helen Goergen, et al.
Blood|June 17, 2010
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Teresa V Halbsguth, Lucia Nogová, Horst Mueller, et al.
Annals of Surgery|June 24, 2004
Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trialHartmut Schaefer, Andreas Engert, Guido Grass, et al.
Leukemia & Lymphoma|October 22, 2013
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantBastian von Tresckow, Horst Müller, Dennis A Eichenauer, et al.
European Journal of Haematology|October 23, 2018
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignanciesBastian von Tresckow, Cyrus Sayehli, Walter E Aulitzky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2019
Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin LymphomaSven Borchmann, Melita Cirillo, Helen Goergen, et al.
Pageof 38

Showing results (221-230 of 379) with videos related to

Sort By:
Pageof 38
Immunotherapy|March 31, 2017
Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doorsChristian Baues, Maike Trommer-Nestler, Karolina Jablonska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2015
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin LymphomaBastian von Tresckow, Franck Morschhauser, Vincent Ribrag, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Plos One|October 15, 2008
Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer functionVenkateswara Rao Simhadri, Katrin S Reiners, Hinrich P Hansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 TrialsStephanie Sasse, Paul J Bröckelmann, Helen Goergen, et al.
Blood|June 17, 2010
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Teresa V Halbsguth, Lucia Nogová, Horst Mueller, et al.
Annals of Surgery|June 24, 2004
Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trialHartmut Schaefer, Andreas Engert, Guido Grass, et al.
Leukemia & Lymphoma|October 22, 2013
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplantBastian von Tresckow, Horst Müller, Dennis A Eichenauer, et al.
European Journal of Haematology|October 23, 2018
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignanciesBastian von Tresckow, Cyrus Sayehli, Walter E Aulitzky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2019
Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin LymphomaSven Borchmann, Melita Cirillo, Helen Goergen, et al.
Pageof 38